Cwm LLC Acquires 1,122 Shares of Danaher Co. (NYSE:DHR)

Cwm LLC boosted its stake in shares of Danaher Co. (NYSE:DHR) by 5.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 23,034 shares of the conglomerate’s stock after buying an additional 1,122 shares during the period. Cwm LLC’s holdings in Danaher were worth $5,755,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of DHR. Argus Investors Counsel Inc. lifted its position in Danaher by 4.2% in the 4th quarter. Argus Investors Counsel Inc. now owns 2,925 shares of the conglomerate’s stock valued at $677,000 after acquiring an additional 119 shares in the last quarter. Valley National Advisers Inc. raised its stake in shares of Danaher by 43.9% in the 4th quarter. Valley National Advisers Inc. now owns 423 shares of the conglomerate’s stock valued at $97,000 after purchasing an additional 129 shares during the period. Strategic Blueprint LLC lifted its holdings in shares of Danaher by 4.2% in the fourth quarter. Strategic Blueprint LLC now owns 8,804 shares of the conglomerate’s stock valued at $2,037,000 after purchasing an additional 358 shares in the last quarter. Confluence Wealth Services Inc. boosted its position in shares of Danaher by 3.5% during the fourth quarter. Confluence Wealth Services Inc. now owns 1,930 shares of the conglomerate’s stock worth $446,000 after buying an additional 66 shares during the period. Finally, Pinnacle Bancorp Inc. grew its holdings in shares of Danaher by 25.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 300 shares of the conglomerate’s stock worth $69,000 after buying an additional 60 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR traded down $5.66 during mid-day trading on Wednesday, reaching $263.31. The company’s stock had a trading volume of 2,783,996 shares, compared to its average volume of 2,909,317. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The stock has a market cap of $195.03 billion, a P/E ratio of 44.63, a PEG ratio of 4.62 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The business has a 50-day simple moving average of $256.77 and a two-hundred day simple moving average of $251.78.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.05 EPS. As a group, equities research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on DHR. TD Cowen boosted their target price on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Stifel Nicolaus increased their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Barclays lifted their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. SVB Leerink increased their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, The Goldman Sachs Group lifted their target price on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $276.88.

Insider Activity at Danaher

In other news, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $7,441,441.35. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO Matthew Mcgrew sold 46,377 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,174 shares of company stock worth $29,775,644. Insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.